Ceftolozane / Tazobactam: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France) recommended or restricted ceftolozane / tazobactam, while PHARMAC (New Zealand) and SMC (Scotland) did not recommend it.
On the same population the two systems disagree outright: AWMSG (Wales) recorded restricted for “Treatment of the following infections in adults: complicated intra-abdominal infections; acute pyelonephritis; and compl…”, while SMC (Scotland) recorded not recommended for “For the treatment of the following infections in adults: - Complicated intra-abdominal infections - Acute pyelonephritis - Complicated urinary tract infections”.
Assessment has run over 6.6 years, from 9 May 2016 at SMC (Scotland) to 14 Dec 2022 at HAS (France).
AWMSG (Wales) changed its position: restricted on 27 Jul 2016, not recommended by 18 Feb 2020.
No assessment is on file from PBAC (Australia), TLV (Sweden), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for ceftolozane / tazobactam, 1 submission was never made — an outcome set by the company rather than the assessor.
Against its own class, ceftolozane / tazobactam is an outlier: 57% of its decisive outcomes were positive, where molecules sharing ATC class J01C average 78%.
3 distinct indication wordings are recorded for ceftolozane / tazobactam by the agencies that label one in English (AWMSG and SMC).
The systems moved almost together: all 4 agencies opened a file on ceftolozane / tazobactam within a year of one another, starting with SMC (Scotland) on 9 May 2016.
3 of the 4 agencies here assessed ceftolozane / tazobactam more than once, HAS (France) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 4 of the 18 agencies here have assessed ceftolozane / tazobactam.
The full ledger for ceftolozane / tazobactam reads 3 recommended, 3 not recommended, 1 non-submission and 1 restricted.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 14 Dec 2022 | Indication extension | SMR substantial · ASMR III | source |
| AWMSG (Wales) | 18 Feb 2020 | For the treatment of hospital-acquired pneumonia, including ventilator‑associated pneumonia in adults | not endorsed (non-submission) | source |
| SMC (Scotland) | 9 Dec 2019 | In adults for the treatment of hospital acquired pneumonia, including ventilator-associated pneumonia. | not recommended | source |
| PHARMAC (New Zealand) | 9 Feb 2017 | Complicated intra -abdominal infections, complicated urinary tract infections | PTAC advice: Decline · decision reached | source |
| AWMSG (Wales) | 27 Jul 2016 | Treatment of the following infections in adults: complicated intra-abdominal infections; acute pyelonephritis; and compl… | recommended with restrictions (full) | source |
3 further decisions for ceftolozane / tazobactam, across 2 agencies, are not shown here. They link to 1 further source document.
Related molecules
- pivmecillinam — same ATC class J01C — Antibacterials
- benzathine benzylpenicillin — same ATC class J01C — Antibacterials
- eptinezumab — also decided by HAS in 2022Q4
- vutrisiran — also decided by HAS in 2022Q4
- somatrogon — also decided by HAS in 2022Q4
- bimatoprost — also decided by HAS in 2022Q4
Coverage: 8 decisions for ceftolozane / tazobactam from 4 agencies, 2016 to 2022. Data to 7 Sep 2026. ATC class J01C — Antibacterials. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.